Chinook Therapeutics is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing precision medicines for kidney diseases. Co.'s pipeline is focused on kidney diseases with clinical pathways. Co.'s lead clinical program is atrasentan, an endothelin A receptor antagonist. Co.'s second product candidate, BION-1301, is an anti-APRIL monoclonal antibody also in development for patients with IgA nephropathy. Co. developing CHK-336 for the treatment of primary hyperoxaluria as well as secondary hyperoxaluria and idiopathic kidney stone formation. Co. is also conducting research programs in several other rare, severe chronic kidney diseases. We show 13 historical shares outstanding datapoints in our KDNY shares outstanding history coverage, used to compute KDNY market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing KDNY market cap history over the course of time is important for investors
interested in comparing KDNY's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of KDNY versus a peer is one thing; comparing
KDNY market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like KDNY can fluctuate over the course of history.
With this page we aim to empower investors researching KDNY by allowing them to research the KDNY market cap history. |
Free KDNY Email Alerts:
Video: The Importance of Market Cap
